Dr. William Muller, Goodman Cancer Research Centre
Dr. William Muller, Professor


Rosalind and Morris Goodman Cancer Research Centre

1160 Pine Avenue
Office: Room 516; Lab: Room 507
Montreal, Quebec H3A 1A3

Tel. (514) 398-5847
Lab: (514) 398-4512
Fax: (514) 398-6769




Rosalind and Morris Goodman Cancer Research Centre
Department of Biochemistry
McGill University


1. National Cancer Institute of Canada, Research Scientist Award, 1989-1995
2. Medical Research Council of Canada, MRC Scientist Award, 1996-2001
3. CRC Chair in Molecular Oncology, McGill University, 2002-2016
4. Fellow of the Royal Society of Canada, 2011



Dr. Muller’s laboratory focuses on the area of mouse models of breast cancer progression. The progression of the primary mammary epithelial cell to malignant phenotype involves multiple genetic events including the activation of dominant activating oncogenes and inactivation of specific tumour suppressor genes. Dr. Muller’s laboratory focuses on the role of a class of receptor tyrosine kinases known as the epidermal growth factor receptor (EGFR) family in the induction of breast cancer. Elevated expression of the various EGFR family members has been observed in a large proportion of sporadic breast cancers and their derived cell lines. For example, amplification and over-expression of erbB-2/neu proto-oncogene is observed in 20-30% human breast cancer and is inversely correlated with the survival of the patient.

The major focus of Dr. Muller’s team is to determine the relative contribution of the various EGFR family members and their coupled signaling pathways in ErbB-2 induced mammary tumour progression. Given the fact that germline inactivation of these signaling pathways results in either embryonic or perinatal lethality, they have used use the Cre/Lox recombination system to specifically inactivate each of these signaling molecules members in the mammary epithelium of mice expressing activated erbB-2.

The results of these biochemical and genetic analyses will provide important insight in molecular basis for erbB-2 induced tumorigenesis and metastasis.

Dr. Muller has made several major research accomplishments recently. His group demonstrated that mammary specific disruption of •1 integrin resulted in the complete elimination of mammary tumours in a transgenic mouse model of human breast cancer. They further demonstrated that the •4 integrin molecule was involved in tumour induction and that integrin coupled FAK signaling molecule played a critical role in conversion of pre-malignant hyperplasias to breast cancer. Finally, Dr. Muller’s group showed that the ShcA adapter was critical for ErbB-2 breast cancer progression.


In addition to the above, the Muller laboratory has demonstrated that both integrin linked kinase and ErbB-2 are required for normal cardiac development.

Figure 1 B1 integrin is retained in PyV mT tumor cells

Figure 2. PyV MT and ErbB2 target different stem cell compartments within the mammary glans